创胜集团-B将出席奥本海默第36届年度医疗健康生命科学大会

Core Viewpoint - The company announced participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, where management will discuss strategic outcomes for 2026 and provide updates on ongoing business development and operational excellence plans [1] Group 1: Strategic Partnerships and Developments - The company successfully executed a strategic cooperation and non-exclusive technology licensing agreement with TaiKang Biotechnology Co., Ltd. in December 2025, receiving upfront payments from this collaboration [1] - In-depth discussions are ongoing with several global and regional pharmaceutical companies regarding the development and commercialization of core assets, with multiple parties currently conducting due diligence or negotiating contracts [1] - The company has attracted interest from global and regional investment institutions, with several currently engaged in active negotiations for financing related to the company and multiple assets [1] Group 2: Operational Efficiency and Cost Management - The company implemented resource integration measures, resulting in a reduction of approximately 16% in employee numbers by December 31, 2025, compared to December 31, 2024, and a 34% decrease in labor, R&D, and other operational expenses [1] - These measures are estimated to save RMB 19 million in costs for Q4 2025 compared to Q4 2024, thereby improving operational efficiency and extending the company's cash runway [1] - The company successfully negotiated repayment extensions and/or revised schedules with three suppliers for a total of approximately RMB 10 million, extending payment dates by an average of over 130 days [1] Group 3: Financial Management and Capital Flexibility - The company maintains good relationships with banking partners to support the renewal and extension of loan financing, having renewed bank financing of RMB 77 million and secured new financing of RMB 15 million since the last update in October 2025 [1] - Ongoing discussions with three additional financial institutions for further credit lines are expected to enhance the company's capital flexibility and support daily operations and R&D expenditures [1]